Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
To the Editor: The pharmaceutical industry
in Australia is certainly aware that pharmacoeconomic analyses are complex
and difficult to evaluate, as stated in the article by Dr Hill and colleagues,1 but we disagree with its conclusions. It is also
not obvious from the article that at least 2 of the authors were involved
previously in more than 1 stage of the analysis of each submission. This brings
their perspective into question.
Stafford M. Problems in Pharmacoeconomic Analyses—Reply. JAMA. 2000;284(15):1922-1924. doi:10.1001/jama.284.15.1921